Heart-Safe CLL treatment? study switches patients to acalabrutinib
NCT ID NCT06757647
First seen Nov 12, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tests whether acalabrutinib, a targeted cancer drug, can control chronic lymphocytic leukemia (CLL) without the heart side effects often caused by a similar drug, ibrutinib. About 61 adults with CLL who had heart problems on ibrutinib will switch to acalabrutinib. Researchers will use heart MRIs to check if heart function improves or stays stable, while also monitoring how well the cancer is controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.